Recce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to provide a notice of change of interests in Director holdings.
The Company advises that Chief Executive Officer James Graham has increased his shareholding through the on-market purchase of an additional 500,000 shares totaling AUD $306,871.75.
| 19th June – 22nd June 2023 | ||||
| Person whose relevant interest changed | Price per share | Quantity On | Value ($) | |
| James Graham (CEO & Managing Director) | 0.566419 | 89,303 | $ | 50,582.92 |
| 0.621541 | 248,955 | $ | 154,735.74 | |
| 0.62980 | 80,403 | $ | 50,637.81 | |
| 0.625964 | 81,339 | $ | 50,915.29 | |
| Total | 500,000 | $ | 306,871.75 | |
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | Recce Pharmaceuticals Ltd (Company) |
| ACN | 124 849 065 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | James Graham |
| Date of last notice | 22 June 2021 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | Direct and indirect interest |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | Buttonwood Nominees Pty Ltd with the shares being held on behalf of James Graham |
| Date of change | a) 25 August 2022 (transfer) b) 25 August 2022 (transfer) c) 15 June 2023 (transfer) d) 19 June 2023 e) 20 June 2023 f) 21 June 2023 g) 22 June 2023 |
| No. of securities held prior to change | Direct Interest |
| 1. 2,840,332 fully paid ordinary shares | |
| 2. 389,712 Class B Performance Shares | |
| 3. 2,250,000 Unlisted Options | |
| Indirect Interest | |
| Mr. James Graham | |
| 1. 2,493,750 fully paid ordinary shares | |
| 2. 356,250 Class B Performance Shares | |
| Bulleen Pty Ltd | |
| 1. 697,850 fully paid ordinary shares | |
| Class | Fully paid ordinary shares |
| Number acquired | 500,000 fully paid ordinary shares |
| Number disposed | Nil |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | a) $50,582.92 b) $154,735.74 c) $50,637.81 d) $50,915.29 |
| No. of securities held after change | Total number of fully paid ordinary shares held after change: 6,531,932 |
| Direct Interest | |
| 1. 262,347 fully paid ordinary shares | |
| 2. 389,712 Class B Performance Shares | |
| 3. 2,250,000 Unlisted Options | |
| Indirect Interest | |
| Mr. James Graham | |
| 1. 356,250 Class B Performance Shares | |
| Bulleen Pty Ltd | |
| 1. 769,585 fully paid ordinary shares | |
| Buttonwood Nominees Pty Ltd | |
| 1. 5,500,000 fully paid ordinary shares | |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back |
|
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
| Nature of interest | N/A |
| Name of registered holder (if issued securities) | N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| Interest after change | N/A |
Part 3 – +Closed period
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided? | N/A |
+ See chapter 19 for defined terms.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE® 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE® 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.
Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
Media & Investor Relations (AU)
Andrew Geddes
CityPR
+61 (02) 9267 4511
Media (USA)
Jordyn Temperato
LifeSci Communications
Investor Relations (USA & EU)
Guillame van Renterghem
LifeSci Advisors
